Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences to Acquire Immunomedics for $21 Billion in Cash

By Cory Renauer – Sep 13, 2020 at 10:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big purchase adds one of the year's most highly anticipated new cancer therapies to Gilead's product line.

Gilead Sciences' (GILD -1.22%) mission to create a better oncology portfolio took a big step forward on Sunday. The company best known for antiviral treatments made Immunomedics (IMMU) a juicy buyout offer that values the recently successful cancer drug developer at $21 billion.

Immunomedics shareholders will receive $88 per share in cash from Gilead Sciences when the deal closes, most likely before the end of the year. The price Gilead offered is 108% more than Immunomedics' most recent closing price.

Hands exchanging money.

Image source: Getty Images.

Acquiring Immunomedics will add the recently approved breast cancer treatment, Trodelvy, to an oncology lineup at Gilead that generated sales of just $334 million in the first half of 2020. Trodelvy is an antibody-drug conjugate that delivers a dose of chemotherapy directly to tumor cells after recognizing a protein called Trop-2 commonly found on their surface.

In April, the FDA approved Trodelvy as the first available treatment for the underserved population of patients with triple-negative breast cancer (TNBC), and Trop-2 is also known to appear on tumors that originate in the pancreas and bladder. As a first available treatment for cancer patients who lack effective options, annual sales of Trodelvy are expected to reach $2.3 billion by 2026.  

The FDA granted Trodelvy accelerated approval based on impressive tumor response rates from a single-arm trial with 108 advanced-stage TNBC patients who had already received at least two previous lines of therapy. Immunomedics will present longer-term survival results at the virtual meeting of the European Society for Medical Oncology, which will take place Sept. 19-21.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Immunomedics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences Stock Quote
Gilead Sciences
$85.21 (-1.22%) $-1.05
Immunomedics Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.